126 related articles for article (PubMed ID: 17357475)
1. Comparison of properties of tumor necrosis factor-alpha converting enzyme (TACE) and some matrix metalloproteases (MMPs) in catalytic domains.
Zhao Y; Feng W; Yang Y; Ling L; Chen R
J Huazhong Univ Sci Technolog Med Sci; 2006; 26(6):637-9. PubMed ID: 17357475
[TBL] [Abstract][Full Text] [Related]
2. Pronounced diversity in electronic and chemical properties between the catalytic zinc sites of tumor necrosis factor-alpha-converting enzyme and matrix metalloproteinases despite their high structural similarity.
Solomon A; Rosenblum G; Gonzales PE; Leonard JD; Mobashery S; Milla ME; Sagi I
J Biol Chem; 2004 Jul; 279(30):31646-54. PubMed ID: 15102849
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the binding sites of matrix metalloproteinases and tumor necrosis factor-alpha converting enzyme: implications for selectivity.
Lukacova V; Zhang Y; Kroll DM; Raha S; Comez D; Balaz S
J Med Chem; 2005 Apr; 48(7):2361-70. PubMed ID: 15801829
[TBL] [Abstract][Full Text] [Related]
4. Design of selective TACE inhibitors using molecular docking studies: Synthesis and preliminary evaluation of anti-inflammatory and TACE inhibitory activity.
Sarkate AP; Murumkar PR; Lokwani DK; Kandhare AD; Bodhankar SL; Shinde DB; Bothara KG
SAR QSAR Environ Res; 2015; 26(11):905-23. PubMed ID: 26588187
[TBL] [Abstract][Full Text] [Related]
5. Reactive site mutations in tissue inhibitor of metalloproteinase-3 disrupt inhibition of matrix metalloproteinases but not tumor necrosis factor-alpha-converting enzyme.
Wei S; Kashiwagi M; Kota S; Xie Z; Nagase H; Brew K
J Biol Chem; 2005 Sep; 280(38):32877-82. PubMed ID: 16079149
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases (MMPs) in health and disease: an overview.
Malemud CJ
Front Biosci; 2006 May; 11():1696-701. PubMed ID: 16368548
[TBL] [Abstract][Full Text] [Related]
7. Identification of a selectivity determinant for inhibition of tumor necrosis factor-alpha converting enzyme by comparative modeling.
Wasserman ZR; Duan JJ; Voss ME; Xue CB; Cherney RJ; Nelson DJ; Hardman KD; Decicco CP
Chem Biol; 2003 Mar; 10(3):215-23. PubMed ID: 12670535
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.
Pirard B; Matter H
J Med Chem; 2006 Jan; 49(1):51-69. PubMed ID: 16392792
[TBL] [Abstract][Full Text] [Related]
9. Blockade of tumor necrosis factor-alpha-converting enzyme improves experimental small intestinal damage by decreasing matrix metalloproteinase-3 production in rats.
Matsumoto H; Koga H; Iida M; Tarumi K; Fujita M; Haruma K
Scand J Gastroenterol; 2006 Nov; 41(11):1320-9. PubMed ID: 17060126
[TBL] [Abstract][Full Text] [Related]
10. Structural determinants of the ADAM inhibition by TIMP-3: crystal structure of the TACE-N-TIMP-3 complex.
Wisniewska M; Goettig P; Maskos K; Belouski E; Winters D; Hecht R; Black R; Bode W
J Mol Biol; 2008 Sep; 381(5):1307-19. PubMed ID: 18638486
[TBL] [Abstract][Full Text] [Related]
11. The application of x-ray, NMR, and molecular modeling in the design of MMP inhibitors.
Rush TS; Powers R
Curr Top Med Chem; 2004; 4(12):1311-27. PubMed ID: 15320728
[TBL] [Abstract][Full Text] [Related]
12. Structure-based rational design of peptide hydroxamic acid inhibitors to target tumor necrosis factor-α converting enzyme as potential therapeutics for hepatitis.
Wu D; Gu Q; Zhao N; Xia F; Li Z
J Drug Target; 2015 Dec; 23(10):936-42. PubMed ID: 26061299
[TBL] [Abstract][Full Text] [Related]
13. Discovery of selective phosphonamide-based inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Sawa M; Kurokawa K; Inoue Y; Kondo H; Yoshino K
Bioorg Med Chem Lett; 2003 Jun; 13(12):2021-4. PubMed ID: 12781187
[TBL] [Abstract][Full Text] [Related]
14. MT1-MMP mediates MUC1 shedding independent of TACE/ADAM17.
Thathiah A; Carson DD
Biochem J; 2004 Aug; 382(Pt 1):363-73. PubMed ID: 15130087
[TBL] [Abstract][Full Text] [Related]
15. Drosophila TIMP is a potent inhibitor of MMPs and TACE: similarities in structure and function to TIMP-3.
Wei S; Xie Z; Filenova E; Brew K
Biochemistry; 2003 Oct; 42(42):12200-7. PubMed ID: 14567681
[TBL] [Abstract][Full Text] [Related]
16. The P2/P2' sites affect the substrate cleavage of TNF-α converting enzyme (TACE).
Liu S; Liu S; Wang Y; Liao Z
Mol Immunol; 2014 Nov; 62(1):122-8. PubMed ID: 24980871
[TBL] [Abstract][Full Text] [Related]
17. Effects of culture conditions and exposure to catabolic stimulators (IL-1 and retinoic acid) on the expression of matrix metalloproteinases (MMPs) and disintegrin metalloproteinases (ADAMs) by articular cartilage chondrocytes.
Flannery CR; Little CB; Caterson B; Hughes CE
Matrix Biol; 1999 Jun; 18(3):225-37. PubMed ID: 10429942
[TBL] [Abstract][Full Text] [Related]
18. Novel methods and strategies in the discovery of TACE inhibitors.
Murumkar PR; Giridhar R; Yadav MR
Expert Opin Drug Discov; 2013 Feb; 8(2):157-81. PubMed ID: 23231541
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis.
Zhang Y; Xu J; Levin J; Hegen M; Li G; Robertshaw H; Brennan F; Cummons T; Clarke D; Vansell N; Nickerson-Nutter C; Barone D; Mohler K; Black R; Skotnicki J; Gibbons J; Feldmann M; Frost P; Larsen G; Lin LL
J Pharmacol Exp Ther; 2004 Apr; 309(1):348-55. PubMed ID: 14718605
[TBL] [Abstract][Full Text] [Related]
20. Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Rabinowitz MH; Andrews RC; Becherer JD; Bickett DM; Bubacz DG; Conway JG; Cowan DJ; Gaul M; Glennon K; Lambert MH; Leesnitzer MA; McDougald DL; Moss ML; Musso DL; Rizzolio MC
J Med Chem; 2001 Nov; 44(24):4252-67. PubMed ID: 11708926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
